SLC5A2 and type 2 diabetes mellitus: This systematic review aims to evaluate the correlation between empagliflozin (SGLT2 inhibitor) and reductions in mortality and hospitalization rates in patients with and without type 2 diabetes after suffering from acute MI compared to placebo.